Last reviewed · How we verify
HBIG
At a glance
| Generic name | HBIG |
|---|---|
| Sponsor | University Health Network, Toronto |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B (EARLY_PHASE1)
- Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors (PHASE4)
- Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins (PHASE2)
- A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. (PHASE3)
- Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads (NA)
- Prevention of Recurrent Hepatitis B After Liver Transplantation
- Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates (PHASE2)
- Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBIG CI brief — competitive landscape report
- HBIG updates RSS · CI watch RSS
- University Health Network, Toronto portfolio CI